---
document_datetime: 2025-12-02 05:48:14
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ocaliva.html
document_name: ocaliva.html
version: success
processing_time: 0.2730871
conversion_datetime: 2025-12-27 09:51:58.753482
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ocaliva

[RSS](/en/individual-human-medicine.xml/66724)

##### Revoked

This medicine's authorisation has been revoked

obeticholic acid Medicine Human Revoked

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Ocaliva](#news-on)
- [More information on Ocaliva](#more-information-on-ocaliva-71978)
- [More information on Ocaliva](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

The marketing authorization of Ocaliva was revoked by the Commission Implementing Decision of 30 August 2024.

Ocaliva : EPAR - Summary for the public

English (EN) (175.36 KB - PDF)

**First published:** 19/12/2016

**Last updated:** 20/01/2025

[View](/en/documents/overview/ocaliva-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-983)

български (BG) (244.89 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/bg/documents/overview/ocaliva-epar-summary-public_bg.pdf)

español (ES) (174.65 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/es/documents/overview/ocaliva-epar-summary-public_es.pdf)

čeština (CS) (214.92 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/cs/documents/overview/ocaliva-epar-summary-public_cs.pdf)

dansk (DA) (167.05 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/da/documents/overview/ocaliva-epar-summary-public_da.pdf)

Deutsch (DE) (178.84 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/de/documents/overview/ocaliva-epar-summary-public_de.pdf)

eesti keel (ET) (161.72 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/et/documents/overview/ocaliva-epar-summary-public_et.pdf)

ελληνικά (EL) (256.42 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/el/documents/overview/ocaliva-epar-summary-public_el.pdf)

français (FR) (175.94 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/fr/documents/overview/ocaliva-epar-summary-public_fr.pdf)

hrvatski (HR) (203 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/hr/documents/overview/ocaliva-epar-summary-public_hr.pdf)

italiano (IT) (170.01 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/it/documents/overview/ocaliva-epar-summary-public_it.pdf)

latviešu valoda (LV) (214.94 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/lv/documents/overview/ocaliva-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (218.27 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/lt/documents/overview/ocaliva-epar-summary-public_lt.pdf)

magyar (HU) (200.8 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/hu/documents/overview/ocaliva-epar-summary-public_hu.pdf)

Malti (MT) (225.27 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/mt/documents/overview/ocaliva-epar-summary-public_mt.pdf)

Nederlands (NL) (174.96 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/nl/documents/overview/ocaliva-epar-summary-public_nl.pdf)

polski (PL) (217.59 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/pl/documents/overview/ocaliva-epar-summary-public_pl.pdf)

português (PT) (173.38 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/pt/documents/overview/ocaliva-epar-summary-public_pt.pdf)

română (RO) (221.53 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/ro/documents/overview/ocaliva-epar-summary-public_ro.pdf)

slovenčina (SK) (212.57 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/sk/documents/overview/ocaliva-epar-summary-public_sk.pdf)

slovenščina (SL) (206.33 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/sl/documents/overview/ocaliva-epar-summary-public_sl.pdf)

Suomi (FI) (164.65 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/fi/documents/overview/ocaliva-epar-summary-public_fi.pdf)

svenska (SV) (169.61 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/sv/documents/overview/ocaliva-epar-summary-public_sv.pdf)

Ocaliva : EPAR - Risk management plan summary

English (EN) (453.6 KB - PDF)

**First published:** 17/11/2021

**Last updated:** 20/01/2025

[View](/en/documents/rmp-summary/ocaliva-epar-risk-management-plan-summary_en.pdf)

## Product information

Ocaliva : EPAR - Product Information

English (EN) (1.19 MB - PDF)

**First published:** 19/12/2016

**Last updated:** 20/01/2025

[View](/en/documents/product-information/ocaliva-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-294)

български (BG) (1.56 MB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/bg/documents/product-information/ocaliva-epar-product-information_bg.pdf)

español (ES) (1.49 MB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/es/documents/product-information/ocaliva-epar-product-information_es.pdf)

čeština (CS) (1.56 MB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/cs/documents/product-information/ocaliva-epar-product-information_cs.pdf)

dansk (DA) (1.37 MB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/da/documents/product-information/ocaliva-epar-product-information_da.pdf)

Deutsch (DE) (1.43 MB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/de/documents/product-information/ocaliva-epar-product-information_de.pdf)

eesti keel (ET) (1.3 MB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/et/documents/product-information/ocaliva-epar-product-information_et.pdf)

ελληνικά (EL) (1.89 MB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/el/documents/product-information/ocaliva-epar-product-information_el.pdf)

français (FR) (1.56 MB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/fr/documents/product-information/ocaliva-epar-product-information_fr.pdf)

hrvatski (HR) (1.59 MB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/hr/documents/product-information/ocaliva-epar-product-information_hr.pdf)

íslenska (IS) (1.34 MB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/is/documents/product-information/ocaliva-epar-product-information_is.pdf)

italiano (IT) (1.49 MB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/it/documents/product-information/ocaliva-epar-product-information_it.pdf)

latviešu valoda (LV) (1.61 MB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/lv/documents/product-information/ocaliva-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.58 MB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/lt/documents/product-information/ocaliva-epar-product-information_lt.pdf)

magyar (HU) (1.61 MB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/hu/documents/product-information/ocaliva-epar-product-information_hu.pdf)

Malti (MT) (1.77 MB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/mt/documents/product-information/ocaliva-epar-product-information_mt.pdf)

Nederlands (NL) (1.47 MB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/nl/documents/product-information/ocaliva-epar-product-information_nl.pdf)

norsk (NO) (1.36 MB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/no/documents/product-information/ocaliva-epar-product-information_no.pdf)

polski (PL) (1.66 MB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/pl/documents/product-information/ocaliva-epar-product-information_pl.pdf)

português (PT) (1.44 MB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/pt/documents/product-information/ocaliva-epar-product-information_pt.pdf)

română (RO) (1.65 MB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/ro/documents/product-information/ocaliva-epar-product-information_ro.pdf)

slovenčina (SK) (1.57 MB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/sk/documents/product-information/ocaliva-epar-product-information_sk.pdf)

slovenščina (SL) (1.52 MB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/sl/documents/product-information/ocaliva-epar-product-information_sl.pdf)

Suomi (FI) (1.35 MB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/fi/documents/product-information/ocaliva-epar-product-information_fi.pdf)

svenska (SV) (1.39 MB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/sv/documents/product-information/ocaliva-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0048 16/04/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ocaliva : EPAR - All Authorised presentations

English (EN) (56.54 KB - PDF)

**First published:** 19/12/2016

**Last updated:** 20/01/2025

[View](/en/documents/all-authorised-presentations/ocaliva-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-381)

български (BG) (91.25 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/bg/documents/all-authorised-presentations/ocaliva-epar-all-authorised-presentations_bg.pdf)

español (ES) (77.7 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/es/documents/all-authorised-presentations/ocaliva-epar-all-authorised-presentations_es.pdf)

čeština (CS) (60.89 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/cs/documents/all-authorised-presentations/ocaliva-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (52.88 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/da/documents/all-authorised-presentations/ocaliva-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (53.8 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/de/documents/all-authorised-presentations/ocaliva-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (55.05 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/et/documents/all-authorised-presentations/ocaliva-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (89.95 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/el/documents/all-authorised-presentations/ocaliva-epar-all-authorised-presentations_el.pdf)

français (FR) (54.01 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/fr/documents/all-authorised-presentations/ocaliva-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (76.51 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/hr/documents/all-authorised-presentations/ocaliva-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (52.19 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/is/documents/all-authorised-presentations/ocaliva-epar-all-authorised-presentations_is.pdf)

italiano (IT) (54.1 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/it/documents/all-authorised-presentations/ocaliva-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (76.52 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/lv/documents/all-authorised-presentations/ocaliva-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (73.41 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/lt/documents/all-authorised-presentations/ocaliva-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (62.12 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/hu/documents/all-authorised-presentations/ocaliva-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (73.07 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/mt/documents/all-authorised-presentations/ocaliva-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (52.24 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/nl/documents/all-authorised-presentations/ocaliva-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (52.61 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/no/documents/all-authorised-presentations/ocaliva-epar-all-authorised-presentations_no.pdf)

polski (PL) (61.61 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/pl/documents/all-authorised-presentations/ocaliva-epar-all-authorised-presentations_pl.pdf)

português (PT) (54.97 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/pt/documents/all-authorised-presentations/ocaliva-epar-all-authorised-presentations_pt.pdf)

română (RO) (71.14 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/ro/documents/all-authorised-presentations/ocaliva-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (72.18 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/sk/documents/all-authorised-presentations/ocaliva-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (61.78 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/sl/documents/all-authorised-presentations/ocaliva-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (52.16 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/fi/documents/all-authorised-presentations/ocaliva-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (52.92 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/sv/documents/all-authorised-presentations/ocaliva-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ocaliva Active substance obeticholic acid International non-proprietary name (INN) or common name obeticholic acid Therapeutic area (MeSH) Liver Cirrhosis, Biliary Anatomical therapeutic chemical (ATC) code A05AA04

### Pharmacotherapeutic group

Bile and liver therapy

### Therapeutic indication

Ocaliva is indicated for the treatment of primary biliary cholangitis (also known as primary biliary cirrhosis) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.

## Authorisation details

EMA product number EMEA/H/C/004093

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

Marketing authorisation holder

Advanz Pharma Limited

Unit 17 Northwood House Northwood Crescent Dublin 9 D09 V504 Ireland

Opinion adopted 13/10/2016 Marketing authorisation issued 12/12/2016 Revocation of marketing authorisation 30/08/2024 Revision 21

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ocaliva : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (1.57 MB - PDF)

**First published:** 13/06/2017

**Last updated:** 20/01/2025

[View](/en/documents/procedural-steps-after/ocaliva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Ocaliva-H-C-004093-II-0038 : EPAR - Refusal assessment report - variation

Adopted

Reference Number: EMA/528620/2023

English (EN) (22.98 MB - PDF)

**First published:** 18/01/2024

**Last updated:** 20/01/2025

[View](/en/documents/variation-report/ocaliva-h-c-004093-ii-0038-epar-refusal-assessment-report-variation_en.pdf)

Ocaliva-H-C-PSUSA-00010555-201706 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/289133/2018

English (EN) (116.47 KB - PDF)

**First published:** 14/05/2018

**Last updated:** 20/01/2025

[View](/en/documents/scientific-conclusion/ocaliva-h-c-psusa-00010555-201706-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Ocaliva : EPAR - Conclusions on the granting of the conditional marketing authorisation

English (EN) (158.23 KB - PDF)

**First published:** 19/12/2016

**Last updated:** 20/01/2025

[View](/en/documents/scientific-conclusion/ocaliva-epar-conclusions-granting-conditional-marketing-authorisation_en.pdf)

[Other languages (24)](#file-language-dropdown-363)

български (BG) (255.86 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/bg/documents/scientific-conclusion/ocaliva-epar-conclusions-granting-conditional-marketing-authorisation_bg.pdf)

español (ES) (159.07 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/es/documents/scientific-conclusion/ocaliva-epar-conclusions-granting-conditional-marketing-authorisation_es.pdf)

čeština (CS) (217.91 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/cs/documents/scientific-conclusion/ocaliva-epar-conclusions-granting-conditional-marketing-authorisation_cs.pdf)

dansk (DA) (159.4 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/da/documents/scientific-conclusion/ocaliva-epar-conclusions-granting-conditional-marketing-authorisation_da.pdf)

Deutsch (DE) (161.9 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/de/documents/scientific-conclusion/ocaliva-epar-conclusions-granting-conditional-marketing-authorisation_de.pdf)

eesti keel (ET) (155.06 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/et/documents/scientific-conclusion/ocaliva-epar-conclusions-granting-conditional-marketing-authorisation_et.pdf)

ελληνικά (EL) (234.28 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/el/documents/scientific-conclusion/ocaliva-epar-conclusions-granting-conditional-marketing-authorisation_el.pdf)

français (FR) (161.27 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/fr/documents/scientific-conclusion/ocaliva-epar-conclusions-granting-conditional-marketing-authorisation_fr.pdf)

hrvatski (HR) (224 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/hr/documents/scientific-conclusion/ocaliva-epar-conclusions-granting-conditional-marketing-authorisation_hr.pdf)

íslenska (IS) (153.44 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/is/documents/scientific-conclusion/ocaliva-epar-conclusions-granting-conditional-marketing-authorisation_is.pdf)

italiano (IT) (189.58 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/it/documents/scientific-conclusion/ocaliva-epar-conclusions-granting-conditional-marketing-authorisation_it.pdf)

latviešu valoda (LV) (211.99 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/lv/documents/scientific-conclusion/ocaliva-epar-conclusions-granting-conditional-marketing-authorisation_lv.pdf)

lietuvių kalba (LT) (227.17 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/lt/documents/scientific-conclusion/ocaliva-epar-conclusions-granting-conditional-marketing-authorisation_lt.pdf)

magyar (HU) (235.22 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/hu/documents/scientific-conclusion/ocaliva-epar-conclusions-granting-conditional-marketing-authorisation_hu.pdf)

Malti (MT) (246.14 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/mt/documents/scientific-conclusion/ocaliva-epar-conclusions-granting-conditional-marketing-authorisation_mt.pdf)

Nederlands (NL) (160.44 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/nl/documents/scientific-conclusion/ocaliva-epar-conclusions-granting-conditional-marketing-authorisation_nl.pdf)

norsk (NO) (160.62 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/no/documents/scientific-conclusion/ocaliva-epar-conclusions-granting-conditional-marketing-authorisation_no.pdf)

polski (PL) (218.47 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/pl/documents/scientific-conclusion/ocaliva-epar-conclusions-granting-conditional-marketing-authorisation_pl.pdf)

português (PT) (160.43 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/pt/documents/scientific-conclusion/ocaliva-epar-conclusions-granting-conditional-marketing-authorisation_pt.pdf)

română (RO) (229.26 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/ro/documents/scientific-conclusion/ocaliva-epar-conclusions-granting-conditional-marketing-authorisation_ro.pdf)

slovenčina (SK) (237.4 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/sk/documents/scientific-conclusion/ocaliva-epar-conclusions-granting-conditional-marketing-authorisation_sk.pdf)

slovenščina (SL) (239.76 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/sl/documents/scientific-conclusion/ocaliva-epar-conclusions-granting-conditional-marketing-authorisation_sl.pdf)

Suomi (FI) (155.12 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/fi/documents/scientific-conclusion/ocaliva-epar-conclusions-granting-conditional-marketing-authorisation_fi.pdf)

svenska (SV) (156.85 KB - PDF)

**First published:**

19/12/2016

**Last updated:**

20/01/2025

[View](/sv/documents/scientific-conclusion/ocaliva-epar-conclusions-granting-conditional-marketing-authorisation_sv.pdf)

## Initial marketing authorisation documents

Ocaliva : EPAR - Public assessment report

Adopted

Reference Number: EMA/725757/2016

English (EN) (9.37 MB - PDF)

**First published:** 19/12/2016

**Last updated:** 20/01/2025

[View](/en/documents/assessment-report/ocaliva-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Ocaliva

Adopted

Reference Number: EMA/CHMP/651446/2016

English (EN) (160.81 KB - PDF)

**First published:** 14/10/2016

**Last updated:** 20/01/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-ocaliva_en.pdf)

#### News on Ocaliva

[EMA recommends revoking conditional marketing authorisation for Ocaliva](/en/news/ema-recommends-revoking-conditional-marketing-authorisation-ocaliva) 28/06/2024

[New medicine for rare, chronic liver disease](/en/news/new-medicine-rare-chronic-liver-disease) 14/10/2016

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-october-2016) 14/10/2016

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-3=2=EMEAHC0040930000) (initial marketing authorisation)

#### More information on Ocaliva

This product was originally [designated an orphan medicine](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-753) on 27 July 2010. Ocaliva was withdrawn from the Community register of orphan medicinal products by the European Commission in September 2024 at the time of the revoking of the marketing authorisation.

#### More information on Ocaliva

- [EMEA-001304-PIP02-13-M07 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001304-pip02-13-m07)
- [EMEA-001304-PIP03-17 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001304-pip03-17)
- [Ocaliva - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/ocaliva)
- [Ocaliva - referral](/en/medicines/human/referrals/ocaliva)
- [Ocaliva - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/ocaliva-0)

**This page was last updated on** 20/01/2025

## Share this page

[Back to top](#main-content)